Vertex is redefining the treatment landscape for Type 1 Diabetes (T1D) by moving beyond insulin management toward a functional cure. Through its leadership in islet cell replacement therapy, Vertex leverages cutting-edge stem cell biology to produce fully functional, insulin-producing pancreatic islet cells. By replacing the cells destroyed by the body’s immune system, this investigative approach aims to restore glucose transition and eliminate the need for external insulin injections. With the integration of proprietary encapsulation technologies and gene-editing capabilities, Vertex is dedicated to overcoming the historical barriers of transplant rejection, aiming to deliver a transformative, “one-and-done” solution for millions of patients worldwide.